Safety and tolerability of pioglitazone

Experimental and Clinical Endocrinology and Diabetes

Volumn 108, Issue SUPPL. 2, 2000, Pages

  Belcher, G ^a   Matthews, D R ^b  

^a Takeda Global Research and Development Centre (Europe) Ltd   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adverse event; Pioglitazone; Safety

Indexed keywords

EID: 0000937866     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-8529     Document Type: Article

References (25)

1. Bonora E, Formentini G, Calcaterra F, Marini F, Muggeo M: Homeostasis model assessment of insulin resistance predicts cardiovascular disease in type 2 diabetes mellitus. Diabetes 49 (Suppl 1): A21, 2000
2. Day C: Thiazolidinediones: a new class of antidiabetic drugs. Diabetic Med 16: 179-192, 1999
3. DeFronzo RA: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med 50: 191-197, 1997
4. Despres JP: The insulin resistance-dyslipidemic syndrome of visceral obesity: effect on patients' risk. Obesity Res 6 (Suppl 1): p8S-17S, 1998
5. Dougall HT, McLay J: A comparative review of the adverse effects of calcium antagonists. Drug Saf 15: 91-106, 1996
6. FDA Report: Rezulin to be withdrawn from the market. HHS News, PDA, March 21, 2000
7. Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM: Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 129: 36-38, 1998
8. Haffner SM: Epidemiology of insulin resistance and its relation to coronary artery disease. Am J Cardiol 84: 11J-14J, 1999
9. Haffner SM, D'Agostino R Jr, Mykkanen L, Tracy R, Howard B, Rewers M, Selby J, Savage PJ, Saad MF: Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 22: 562-568, 1999
10. Henry RR: Thiazolidinediones. Endocrinol Metab Clin North Am 26: 553-573, 1997
11. Hirshberg B, Muszkat M, Marom T, Shalit M: Natural course of insulin edema. J Endocrinol Invest 23: 187-188, 2000
12. Hsueh WA, Law RE: Cardiovascular risk continuum: implications of insulin resistance and diabetes. Am J Med 105: 4S-14S, 1998
13. Kawasaki H, Kuroda S, Mimaki Y: [Vascular effects of insulin] [In process citation]. Nippon Yakurigaku Zasshi 115: 287-294, 2000
14. Keen H, Clark C, Laakso M: Reducing the burden of diabetes: Managing cardiovascular disease. Diabetes Metab Rev 15: 186-196, 1999
15. Kemnitz JW, Elson DF, Roecker EB, Baum ST, Bergman RN, Meglasson MD: Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. Diabetes 43: 204-211, 1994
16. Kinoshita J, Tanaka Y, Niwa M, Yoshii H, Takagi M, Kawamori R: Impairment of insulin-induced vasodilation is associated with muscle insulin resistance in type 2 diabetes. Diabetes Res Clin Pract 47: 185-190, 2000
17. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Cusi K, Mandarino L, DeFronzo RA: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in patients with type 2 diabetes mellitus (T2DM). Diabetes 49 (Suppl 1): A299, 2000
18. Montague CT, O'Rahilly S: The perils of portliness: causes and consequences of visceral adiposity. Diabetes 49: 883-888, 2000
19. Neuschwander-Tetri BA, Isley WL, Oki JC, Ramrakhiani S, Quiason SG, Phillips NJ, Brunt EM: Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann Intern Med 129: 38-41, 1998
20. Ravi TS, Nelli P, Rai P, Kundaje GN: Insulin oedema: an uncommon complication of insulin therapy. J Assoc Physicians India 39: 411-412, 1991
21. Shibuya A, Watanabe M, Fujita Y, Saigenji K, Kuwao S, Takahashi H, Takeuchi H: An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care 21: 2140-2143, 1998
22. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 321(7258): 405-412, 2000
23. UKPDS: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853, 1998a
24. UKPDS: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). Br Med J 317: 703-713, 1998b
25. Watkins PB, Whitcomb RW: Hepatic dysfunction associated with troglitazone. N Engl J Med 338: 916-917, 1998